CD274 and neoplasm: Concomitantly, these activate T cells to secrete IFN-γ, which, via the JAK–STAT pathway, upregulates PD-L1 expression and engenders an “immune editing” effect that maintains PD-L1 exposure on residual tumor cells, thus furnishing targets for subsequent immunotherapy (54, 55).